138 related articles for article (PubMed ID: 30722122)
1. Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.
Domae E; Hirai Y; Ikeo T; Goda S; Tsuji K
J BUON; 2018 Dec; 23(7):132-138. PubMed ID: 30722122
[TBL] [Abstract][Full Text] [Related]
2. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Kakimi K; Matsushita H; Masuzawa K; Karasaki T; Kobayashi Y; Nagaoka K; Hosoi A; Ikemura S; Kitano K; Kawada I; Manabe T; Takehara T; Ebisudani T; Nagayama K; Nakamura Y; Suzuki R; Yasuda H; Sato M; Soejima K; Nakajima J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948652
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
[TBL] [Abstract][Full Text] [Related]
6. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
8. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
[TBL] [Abstract][Full Text] [Related]
9. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Dhar S; Chiplunkar SV
Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
Li Z; Peng H; Xu Q; Ye Z
J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
[TBL] [Abstract][Full Text] [Related]
11. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
13. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
14. Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
Sawaisorn P; Gaballa A; Saimuang K; Leepiyasakulchai C; Lertjuthaporn S; Hongeng S; Uhlin M; Jangpatarapongsa K
Sci Rep; 2024 Jan; 14(1):1291. PubMed ID: 38221530
[TBL] [Abstract][Full Text] [Related]
15. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
16. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
17. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
18. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
[TBL] [Abstract][Full Text] [Related]
20. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]